(NCI) Therapeutics (e.g. Small Molecules, Biologics, Radiomodulators, and Cell-based Therapies) In Vitro and In Vivo Diagnostics (e.g. Companion Diagnostics and Prognostic Technologies) Imaging Technologies (e.g. Agents, Devices, and Image-Guided Interventions) Devices for Cancer Therapy (e.g. Interventional Devices, Surgical, Radiation and Ablative Therapies) Agents for Cancer Prevention (e.g., Vaccines, but not “Technologies for Cancer Prevention”) Development of Low Cost Technologies for Global Health Development of Digital Health (NCATS) Innovative platforms for identification and prioritization of targets for therapeutic intervention with clear clinical impact. Technologies to determine alternative uses for existing therapeutic interventions.
skin conductance response, temperature, accelerometer, etc.) time-locked to audio and video data and analyses is also highly desired. Contraception Research Branch Development of innovative contraceptive approaches for both males and females. Developmental Biology and Structural Variation Branch Innovative technologies for imaging developmental processes and gene expression; technologies for gene manipulations and perturbations; and in vivo for quantitative measurement of physical properties of cells and tissues contributing to embryonic morphogenesis. Fertility and Infertility Branch Development of novel techniques for assessment of gamete quality. Gynecologic Health and Disease Branch Development of innovative technologies for the treatment of endometriosis, uterine fibroids, or pelvic floor dysfunction, the latter including pelvic organ prolapse, urinary incontinence or fecal incontinence. Intellectual and Developmental Disabilities Branch Technology development to improve screening, diagnosis and treatment of intellectual and developmental disabilities. Maternal and Pediatric Infectious Disease Branch New technologies relevant to resource-limited countries for screening, diagnosis, and management of HIV and other infectious diseases, including tuberculosis, viral hepatitis, other congenital infections such as cytomegalovirus, respiratory infections, etc., in infants, children and pregnant/breastfeeding women. Development and evaluation of vaccines relevant to HIV and other infectious diseases for infants, children, and pregnant/breastfeeding women. Obstetric and Pediatric Pharmacology and Therapeutics Branch Development of devices to help diagnose or pediatric and pregnancy associated disorders. Pediatric Growth and Nutrition Branch Isolation, purification and synthesis of human milk oligosaccharides and peptides with antimicrobial activity. Develop rapid and reliable methods to test human milk components for antimicrobial activity. Pediatric Trauma and Critical Illness Branch
Development or evaluation of technologies for improving clinical research in Diabetes and Digestive and Kidney Diseases, including technologies for improving data collection and reporting of patient outcomes. Development or evaluation of –omics, informatics, or internet-based technologies for biomedical research or clinical applications in diagnosing or managing Diabetes and Digestive and Kidney Diseases. Development or evaluation of technologies to prevent or cell or tissue injury during other disease states or surgical procedures. (NIDA) 1. Drug (Medication) discovery and development-enabling activities for Substance Use Disorders (SUDs). Innovative in in situ, or in vivo tools for the analysis of the central nervous system, normal and/or diseased. Technologies, including molecular imaging, gene expression profiling, and genotyping and sequencing approaches designed to better inform SUD diagnosis and treatment. Assay development (e.g., biochemical, functional) and validation, especially, hiPSC-based assays, human organoid, or 3-D culture systems with the intention of developing medium to assays. Tools to simplify the design and preclinical development of medications for SUDs. Discovery of SUD-related biomarkers (BMs) (e.g., BMs of chronic drug exposure, pharmacodynamic, toxicological/safety; BM assay development and validation), and device development. Development of BM known to be associated with a health (salutary) outcome, which are quantitatively affected by reduction in drug use are particularly welcome Predictors of clinical outcomes in SUDs, e.g. physiological, electroencephalographic, cognitive tests, and biochemical, epigenetic, and genetic assays. Point of care monitoring systems to improve quantitative assessment of subject adherence to clinical protocols Tools that could be used as quantitative direct (e.g. plasma, saliva, or urine) measures or indirect (e.g. physiological, facial, motor, pupillometry) BMs of drug intoxication. Drug (Medication) discovery and development activities. Application of emerging and existing technologies and platforms for SUD medication development with the focus on products with the potential to minimize drug seeking, compulsive behavior: Early therapeutic discovery activities ranging from Target ID and validation through lead development Preclinical and/or clinical drug development Technologies or formulations to improve medication delivery throughput